Guideline for the diagnosis and management of myelofibrosis

Guideline for the diagnosis and management of myelofibrosis

Show other versions (1)

The guideline group regarding the diagnosis and management of myelofibrosis was selected to be representative of UK-based medical experts, together with a contribution from a single expert from the USA. MEDLINE and EMBASE were searched systematically for publications in English from 1966 until Augus...

Full description

Bibliographic Details
Main Authors:	Reilly, J, Mcmullin, M, Beer, P, Butt, N, Conneally, E, Duncombe, A, Green, A, Michaeel, N, Gilleece, M, Hall, G, Knapper, S, Mead, A, Mesa, R, Sekhar, M, Wilkins, B, Harrison, C
Format:	Journal article
Language:	English
Published:	2012

Similar Items

Guideline for the diagnosis and management of myelofibrosis.
by: Reilly, J, et al.
Published: (2012)

Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
by: Reilly, J, et al.
Published: (2014)

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
by: Reilly, J, et al.
Published: (2014)

Diagnosis and evaluation of prognosis of myelofibrosis: a British Society for Haematology Guideline
by: McLornan, DP, et al.
Published: (2023)

A physician survey on the application of the British Society for Haematology guidelines for the diagnosis and management of myelofibrosis in the UK
by: Harrison, C, et al.
Published: (2019)

A guideline for the diagnosis and management of polycythaemia vera. A British Society for haematology guideline
by: McMullin, M, et al.
Published: (2018)

Practical management of patients with myelofibrosis receiving ruxolitinib.
by: Harrison, C, et al.
Published: (2013)

Guideline for the investigation and management of eosinophilia
by: Butt, N, et al.
Published: (2017)

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
by: Butt, N, et al.
Published: (2019)

Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012
by: Mclornan, D, et al.
Published: (2012)

Allogeneic stem cell transplantation for myelofibrosis in 2012.
by: McLornan, D, et al.
Published: (2012)

Defining disease modification in myelofibrosis in the era of targeted therapy
by: Pemmaraju, N, et al.
Published: (2022)

Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
by: Harrison, C, et al.
Published: (2016)

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis
by: McMullin, M, et al.
Published: (2018)

Modification of British committee for standards in haematology diagnostic criteria for essential thrombocythaemia
by: Harrison, C, et al.
Published: (2014)

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
by: Verstovsek, S, et al.
Published: (2021)

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis
by: Harrison, C, et al.
Published: (2023)

Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies
by: Mesa, RA, et al.
Published: (2023)

Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia.
by: Harrison, C, et al.
Published: (2014)

Spliceosome mutations are common in MPN-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
by: Chowdhury, O, et al.
Published: (2018)

In utero origin of myelofibrosis presenting in adult monozygotic twins
by: Sousos, N, et al.
Published: (2022)

Recent advances in therapies for primary myelofibrosis
by: Vainchenker, W, et al.
Published: (2023)

A single-cell approach to unraveling abnormal megakaryocyte differentiation and function in myelofibrosis
by: Psaila, B, et al.
Published: (2017)

A retrospective real world evidence study to review the current treatment pathways for myelofibrosis from across the United Kingdom (the REALISM UK study)
by: Mead, A, et al.
Published: (2019)

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
by: McIlroy, G, et al.
Published: (2025)

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
by: Mead, AJ, et al.
Published: (2022)

Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 study
by: Gupta, V, et al.
Published: (2018)

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
by: Mesa, R, et al.
Published: (2017)

Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice
by: Lysenko, V, et al.
Published: (2020)

Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia
by: Steensma, D, et al.
Published: (2004)

Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.
by: Steensma, D, et al.
Published: (2005)

RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort
by: O'Sullivan, JM, et al.
Published: (2023)

Equivalence of BCSH and WHO diagnostic criteria for ET
by: Harrison, C, et al.
Published: (2016)

Rapid emergence of chronic lymphocytic leukemia during JAK2 inhibitor therapy in a patient with myelofibrosis
by: Sousos, N, et al.
Published: (2020)

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.
by: Bench, A, et al.
Published: (2013)

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations
by: Bench, A, et al.
Published: (2013)

Absence of mutations in the key megakaryocyte transcriptional regulator FOG-1 in patients with idiopathic myelofibrosis.
by: Fisher, C, et al.
Published: (2004)

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
by: Gerds, AT, et al.
Published: (2020)

ESHRE guideline for the diagnosis and treatment of endometriosis.
by: Kennedy, S, et al.
Published: (2005)

Guidelines for the diagnosis and management of syncope (version 2009).
by: Moya, A, et al.
Published: (2009)